The role of apomorphine SL in the treatment of erectile dysfunction

European Urology, Supplement

Volumn 1, Issue 3, 2002, Pages 4-11

  Montorsi, Francesco ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Apomorphine SL; Erectile dysfunction; Sildenafil

Indexed keywords

APOMORPHINE; CYTOCHROME P450 3A4; ERYTHROMYCIN; KETOCONAZOLE; SILDENAFIL;

ASTHENIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; HYPOTENSION; NAUSEA; NEUROMODULATION; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; SWEATING; SYNCOPE; VASODILATATION; VERTIGO; VOMITING; YAWNING;

EID: 0036590009     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1569-9056(02)00008-8     Document Type: Article

References (39)

1. Mulhall JP. Bukofzer S, Edmonds AL, George M. An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction. Clin Ther 2001;23:1260-71.
2. Solstad K, Hertoft P. Frequency of sexual problems and sexual dysfunction in middle-aged Danish men. Arch Sex Behav 1993;22:51-8.
3. Feldman HA. Goldstein I. Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates; Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
4. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.
5. Lue TF. Erectile dysfunction. N Engl J Med 2000;342:1802-13.
6. Pinnock CB, Stapleton AMF, Marshall VR. Erectile dysfunction in the community: A prevalence study. Med J Aust 1999;171:353-7.
7. Chew KK, Stuckey BGA, Thompson PL, Erectile dysfunction, sildenafil, and cardiovascular risk. Med J Aust 2000;172:279-83.
8. Pritzker RM. The penile stress test: A window to the hearts of man? In: Proceedings of the 72nd American Heart Association. 1999 [Abstract 1045611].
9. Meinhardt W. Kropman RF, Vermeij P, Nijeholt AA, Zwartendijk J. The influence of medication on erectile function. Int J Impot Res 1997;9:17-26.
10. Juenemann K-P, Lue TF, Luo JA, Benowitz NL. Abozeid M, Tanagho EA. The effect of cigarette-smoking on penile erection. J Urol 1987: 138:438-41.
11. Jonas U. The history of erectile dysfunction management. Int J Impot Res 2001;13(Suppl 3):S3-7.
12. Krane RJ. Changes in ED therapy in the Viagra era. World J Urol 2001;19:23-4.
13. Process of Care Consensus Panel. The process of care model for evaluation and treatment of erectile dysfunction. Int J Impot Res 1999;11:59-74.
14. Jardin A, Wagner G, Khour S, Giuliano F. Goldstein I, Padma-Nathan H, et al. Recommendations of the First International Consultation on Erectile Dysfunction. In: Jardin A, Wagner G, Khoury S. Giuliano F, Padma-Nathan H, Rosen R, editors, Erectile Dysfunction. Plymouth (UK): Plymbridge Distributors Ltd., 2000. pp. 711-26.
15. Krane R, Brock G, Eardley I, Fourcroy J, Giuliano F. Hutter A, et al. Oral non-endocrine treatment. In: Jardin A, Wagner G, Khoury S, Giuliano F, Padma-Nathan H, Rosen R, editors. Erectile Dysfunction. Plymouth (UK): Health Publication Ltd., 2000. pp. 241-304.
16. Jarow JP. Patrick NS. Sabbagh M, Eskew A. Outcome analysis of goal-directed therapy for impotence. J Urol 1996;155:1609-12.
17. Heaton JP, Adams MA, Morales A. A therapeutic taxonomy of treatments for erectile dysfunction: An evolutionary perspective. Int J Impot Res 1997;9:115-2.
18. Dula E, Keating W, Siami PF, Edmonds A, O'Neil J. Buttler S, et al. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. Urology 2000;56:130-5.
19. Buvat J, Montorsi F. Safety and tolerability of apomorphine SL in patients with erectile dysfunction. BrJ Urol Int 2001;88(Suppl 3):30-5.
20. Mirone VG, Steif CG. Efficacy of apomorphine SL in erectile dysfunction. Br J Urol Int 2001;88(Suppl 3):25-9.
21. Heaton JPW, Dean J, Sleep DJ. Sequential administration enhances the effect of apomorphine SL in men with erectile dysfunction. Int J Impot Res 2002:14:61-4.
22. Stief C, Padley RJ, Perdok RJ, Sleep DJ. Cross-study review of the clinical efficacy of apomorphine SL 2 and 3 mg: Pooled data from three placebo-controlled, fixed-dose crossover studies. Eur Urol Suppl 2002;1(3):12-20.
23. Ralph DJ, Sleep DJ, Perdok RJ, Padley RJ. Adverse events and patient tolerability of apomorphine SL 2 and 3 mg: A cross-study analysis of phase II and phase III studies. Eur Urol Suppl 2002;1(3):21-7.
24. Adams MA, Perdok RJ, Padley RJ, Sleep DJ. Safety and tolerability of apomorphine SL in men with cardiovascular disorders. Eur Urol Suppl 2002;1(3):28-32.
25. European Agency for the Evaluation of Medicinal Products (EMEA) EPAR document 2001. Available at http://www.eudra.org/humandocs/humans/epar/uprima/uprima.htm. Accessed October, 2001.
26. Walton RP. Lacey C. Absorption of drugs through the oral mucosa. J Pharmacol Exp Ther 1935;54:61-76.
27. Cheitlin MD, Hutter Jr AM. Brindis RG, Ganz P, Kaul S, Russell Jr RO, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999;33:273-82.
28. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30.
29. Dula E. Bukofzer S, Perdok R, George M, The Apomorphine Study Group. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001;39:558-64.
30. McCullough AR, Siegel RL, Shpilsky AB. Intercourse success rates with sildenafil citrate. J Urol 2001;165:A170 [Abstract 699].
31. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999; 162:722-5.
32. Eid JF. Sildenafil citrate: Current clinical experience. Int J Impot Res 2000;12(Suppl 4):S62-6.
33. Muirhead AM, Pearson JG, Rance D, Houston A, Dewland P. Pharmacokinetics of sildenafil (Viagra), a selective cGMP PDE5 inhibitor, after single oral doses in fasting and fed healthy volunteers. Br J Pharmacol 1996;42:268P.
34. Hanson-Divers C. Jackson SE, Lue TF, Crawford SY. Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998;159(5):1541-7.
35. Heaton JPW. Characterizing the benefit of apomorphine SL (Uprima) as an optimized treatment for representative populations with erectile dysfunction. Int J Impot Res 2001;13(Suppl 3):535-9.
36. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res 1998;10:69-73.
37. Goldstein I, Lue T, Padma-Nathan H, Rosen R, Steers W, Wicker P. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338(20):1397-404.
38. Webb D, Boolell M, Muirhead G. Cardiovascular effects of phosphodiesterase type 5 inhibition with concomitant nitrate therapy. Circulation 1998 [abstract].
39. Zusman R, Morales A, Glasser D, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999;83(5A):35C-44C.